PTCT
PTC Therapeutics Inc

4,290
Mkt Cap
$5.58B
Volume
851,776.00
52W High
$87.50
52W Low
$35.95
PE Ratio
8.12
PTCT Fundamentals
Price
$69.45
Prev Close
$70.70
Open
$70.95
50D MA
$75.54
Beta
1.19
Avg. Volume
1.38M
EPS (Annual)
-$4.73
P/B
-35.64
Rev/Employee
$859,190.63
$2,718.39
Loading...
Loading...
News
all
press releases
PTC Therapeutics Pulls Translarna Bid After FDA Flags Weak Proof
PTC Therapeutics, Inc. (PTCT) stock closed lower following the withdrawal of its New Drug Application for Translarna by the FDA.read more...
Benzinga·2d ago
News Placeholder
More News
News Placeholder
PTC Therapeutics Provides Regulatory Update on Translarna
PTC Therapeutics Provides Regulatory Update on Translarna PTC Therapeutics Provides Regulatory Update on Translarna PR Newswire WARREN, N.J., Feb. 12, 2026 WARREN, N.J., Feb. 12, 2026 /PRNewswire...
PR Newswire·2d ago
News Placeholder
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2d ago
News Placeholder
PTC Therapeutics, Inc. $PTCT Stock Position Decreased by BI Asset Management Fondsmaeglerselskab A S
BI Asset Management Fondsmaeglerselskab A S trimmed its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 24.7% during the third quarter, according to its most recent filing with the...
MarketBeat·8d ago
News Placeholder
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday...
PR Newswire·10d ago
News Placeholder
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Analysts
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the sixteen ratings firms that are covering the company, MarketBeat Ratings reports. One...
MarketBeat·13d ago
News Placeholder
Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock?
Kamada (KMDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·19d ago
News Placeholder
Is KROS' KER-065 the Next Breakthrough in DMD Space?
KROS is advancing KER-065 for Duchenne muscular dystrophy, with orphan drug status and a phase II trial planned for early 2026.
Zacks·19d ago
News Placeholder
Sector Gamma AS Increases Position in PTC Therapeutics, Inc. $PTCT
Sector Gamma AS lifted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 28.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange...
MarketBeat·21d ago
News Placeholder
QRG Capital Management Inc. Takes Position in PTC Therapeutics, Inc. $PTCT
QRG Capital Management Inc. acquired a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the third quarter, according to the company in its most recent Form 13F...
MarketBeat·26d ago
<
1
2
...
>

Latest PTCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.